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ORIGINAL RESEARCH
Cardiac Troponin Assays With Improved 
Analytical Quality: A Trade-Off Between 
Enhanced Diagnostic Performance and 
Reduced Long-Term Prognostic Value
Hilde L. Tjora , MD; Ole-Thomas Steiro , MD; Jørund Langørgen, MD, PhD; Rune Bjørneklett , MD, PhD; 
Ottar K. Nygård, MD, PhD; Øyvind Skadberg, MD; Vernon V. S. Bonarjee, MD, PhD; Paul Collinson, MD, PhD; 
Torbjørn Omland , MD, PhD; Kjell Vikenes, MD, PhD; Kristin M. Aakre , MD, PhD
BACKGROUND: Cardiac troponin (cTn) permits early rule-out/rule-in of patients admitted with possible non–ST-segment–eleva-
tion myocardial infarction. In this study, we developed an admission and a 0/1 hour rule-out/rule-in algorithm for a troponin 
assay with measurable results in >99% of healthy individuals. We then compared its diagnostic and long-term prognostic 
properties with other protocols.
METHODS AND RESULTS: Blood samples were collected at 0, 1, 3, and 8 to 12 hours from patients admitted with possible non–
ST-segment–elevation myocardial infarction. cTnT (Roche Diagnostics), cTnI(Abbott) (Abbott Diagnostics), and cTnI(sgx) (Singulex 
Clarity System) were measured in 971 admission and 465 1-hour samples. An admission and a 0/1 hour rule-out/rule-in 
algorithm were developed for the cTnI(sgx) assay and its diagnostic properties were compared with cTnTESC (European Society 
of Cardiology), cTnI(Abbott)ESC, and 2 earlier cTnI(sgx) algorithms. The prognostic composite end point was all-cause mortality and 
future nonfatal myocardial infarction during a median follow-up of 723 days. non–ST-segment–elevation myocardial infarction 
prevalence was 13%. The novel cTnI(sgx) algorithms showed similar performance regardless of time from symptom onset, and 
area under the curve was significantly better than comparators. The cTnI(sgx)0/1 hour algorithm classified 92% of patients to rule-
in or rule-out compared with ≤78% of comparators. Patients allocated to rule-out by the prior published 0/1 hour algorithms 
had significantly fewer long-term events compared with the rule-in and observation groups. The novel cTnI(sgx)0/1 hour algorithm 
used a higher troponin baseline concentration for rule-out and did not allow for prognostication.
CONCLUSIONS: Increasingly sensitive troponin assays may improve identification of non–ST-segment–elevation myocardial 
infarction but could rule-out patients with subclinical chronic myocardial injury. Separate protocols for diagnosis and risk 
prediction seem appropriate.
Key Words: chest pain ■ chronic myocardial injury ■ myocardial infarction ■ 0/1 hour algorithm
Clinical suspicion of non–ST-segment–elevation myocardial infarction (NSTEMI) is a frequent cause of hospital admission,1 and cardiac troponin (cTn, T, or I) measurement is a cornerstone in evaluation of these patients.2 Approximately 40% of patients are “early presenters,”3,4 and accurate detection of low cTn 
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concentrations for immediate rule-out of NSTEMI may 
therefore have clinical utility. The European Society 
of Cardiology (ESC) recommends that patients with 
a detectable baseline cTn concentration undergo se-
rial testing. Based on the baseline and delta concen-
trations obtained, such cases can be classified as 
rule-out, observation, or rule-in for NSTEMI.2 A few 
limitations apply when troponin-based algorithms are 
used for rule-out of NSTEMI, for example, the subopti-
mal analytical sensitivity (unavailability to provide mea-
surable concentrations in all healthy individuals) and 
large analytical imprecision (reproducibility of sequen-
tial measurements) at low troponin concentrations, 
which could produce a false low delta value leading 
to an inappropriate rule-out. Improved analytical sen-
sitivity and precision of these assays might facilitate 
algorithms with higher specificity allowing for admis-
sion rule-out in all individuals with low concentrations 
regardless of time from symptom onset and greater 
reliability of deltas allowing for rule-out in subjects with 
high normal or increased baseline concentrations.
Stable troponin concentrations above the 99th per-
centile is considered to indicate chronic myocardial 
injury (CMI) and are associated with poor long-term 
outcomes.5–7 Studies have shown that risk rises con-
tinuously with troponin concentrations below the 99th 
percentile.8 Some studies have identified this associa-
tion even at concentrations lying between the limit of 
detection (LOD) and limit of blank of current assays.9 
Thus, identifying subclinical myocardial injury (ie, myo-
cardial injury with stable troponin concentration <99th 
percentile) may be of clinical relevance because it could 
indicate increased cardiovascular risk in patients with 
acute chest pain.10–13 Whether assays with improved 
analytical performance could allow for further improve-
ment in long-term risk prediction is not known.
Two previous reports14,15 described findings with a cTn 
assay (Singulex Clarity System) (cTnI(sgx)) with improved 
analytical sensitivity, providing measurable results in 
>99% of healthy individuals (versus corresponding val-
ues of 72% for Roche Diagnostics and 85% for Abbott 
Diagnostics16). This assay also provided 10% analytical 
variation at concentrations below 1 ng/L.16 Neither study, 
however, directly addressed whether this increased 
analytical quality translated into improved clinical utility. 
Although this assay is currently unavailable because the 
company stopped trading in 2019, the data derived from 
it are highly relevant to understand the possible benefits 
and drawbacks of improved analytical quality with tropo-
nin or other cardiac injury biomarker assays.
In this cross-sectional observational study, we hy-
pothesized that compared with currently used or sug-
gested cTnT and cTnI algorithms, cTnI(sgx) could offer 
better performance, with a greater rate of correct 
rule-out and rule-in of patients presenting with possi-
ble NSTEMI. For its development, the admission sam-
ple algorithm should include all patients regardless of 
time between sampling and symptom onset, and the 
0/1 hour algorithm should allow rule-out in patients with 
increased baseline concentration, given low delta val-
ues. Because algorithms using high baseline troponin 
concentration can rule out patients with both subclinical 
myocardial injury and CMI, we also analyzed data from 
a prospective follow-up period to evaluate the relative 
long-term risk-prediction ability of these algorithms.
METHODS
Study Design
The data that support the current findings are avail-
able from the corresponding author upon reasonable 
CLINICAL PERSPECTIVE
What Is New
• Troponin assays with analytical sensitivity and 
precision beyond the current high sensitivity 
troponin assays are likely to show improved di-
agnostic performance for non–ST-segment–el-
evation myocardial infarction (NSTEMI).
• Diagnostic algorithms that are very precise for 
identification of NSTEMI will to a lesser extent 
identify patients with subclinical or overt chronic 
myocardial injury and consequently show lower 
long-term prognostic power compared with 
less precise algorithms.
What Are the Clinical Implications?
• Troponin assays with improved analytical sen-
sitivity have a high ability for early identification 
of NSTEMI, making early presenters with low 
admission troponin concentrations eligible for 
rule-out.
• Development of efficient diagnostic follow-up 
schemes allocating >90% of patients presenting 
with chest pain to rule-in or rule-out for NSTEMI 
should improve the logistics in the emergency 
room.
• Long-term cardiovascular risk should be con-
sidered even in patients who are ruled out for 
NSTEMI.
Nonstandard Abbreviations and Acronyms
CMI chronic myocardial injury
ESC European Society of Cardiology
LOD limit of detection
Sgx Singulex Clarity System
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request. The WESTCOR (Aiming Towards Evidence 
Based Interpretation of Cardiac Biomarkers in Patients 
Presenting With Chest Pain) study (Clinical Trials num-
ber NCT02620202) is a two-center, cross-sectional, 
prospective observational study described in detail 
earlier.17 The cross-sectional study design was used 
to investigate the accuracy of different algorithms. 
Patients were then prospectively followed to determine 
if the different algorithms could predict future cardio-
vascular outcomes.18
The current article reports data from the WESTCOR 
derivation cohort (WESTCOR-D) including 985 patients 
admitted to Haukeland University Hospital, Norway, 
with suspected non−ST-segment elevation acute cor-
onary syndrome (ACS). The inclusion period lasted 
from September 2015 to February 2017. The study and 
biobank were approved by the Regional Committees 
for Medical and Health Research Ethics (2014/1365 
REK West and 2014/1905 REK West).
Study Enrollment and Biobanking
Patients age >18  years admitted with chest pain or 
symptoms suggesting non−ST-segment elevation-
ACS and who did not have a short life expectancy (eg, 
advanced cancer) and could provide informed consent 
were eligible for inclusion.17 Patients had serum sam-
ples drawn on arrival to the emergency department 
and after 3 and 8 to 12 hours. Samples were centri-
fuged after 30 minutes, and material for the biobank 
was aliquoted and frozen. High-sensitivity cTnT was 
measured in fresh samples, and the results were re-
ported to the attending clinician. After an initial period 
of fine-tuning of the study, an additional biobank sam-
ple was drawn 1 hour after admission, and the results 
were not reported to the attending clinician. This ad-
justment was planned a priori as a part of the study.17 
Biobank admission samples were available from 971 
patients, and a 1-hour sample was available for 465 
patients.
Biochemical Analyses
Routine and 1-hour samples were measured for cTnT 
(Roche Diagnostics) with limit of blank 3  ng/L, LOD 
5 ng/L, 99th percentile 14 ng/L, and analytical within-
series coefficient of variation 10% at 4.5  ng/L. For 
cTnI (biobanked samples), measured using the Abbott 
Diagnostics assay (cTnI(Abbott)), these values were 
limit of blank 0.9 ng/L, LOD 1.7 ng/L, 99th percentile 
26 ng/L, and 10% coefficient of variation 4.6 ng/L. For 
the cTnI measured using the Singulex Clarity System, 
these values were limit of blank 0.02  ng/L, LOD 
0.08 ng/L, 99th percentile 8.67 ng/L, and 10% coef-
ficient of variation 0.53 ng/L.16 All other clinical chemis-
try tests were measured using Cobas e602 or Cobas 
8000 from Roche Diagnostics. The glomerular filtration 
rate was estimated using the Chronic Kidney Disease 
Epidemiology Collaboration formula and an enzymatic 
isotope dilution mass spectrometry traceable creati-
nine assay (Roche Diagnostics).
Diagnosis
The diagnostic end point was NSTEMI during the 
index hospitalization. The adjudicating process has 
been described earlier,17 but briefly, 2 independent 
cardiologists adjudicated the final diagnosis based 
on all available clinical, routine laboratory (includ-
ing cTnT at admission and at 3 and 8–12 hours from 
admission), electrocardiogram, ultrasound, and im-
aging findings, including cardiac computed tomo-
graphic angiography and conventional angiography. 
A third adjudicator resolved disagreements. Specific 
diagnostic criteria were predefined for 22 different 
medical conditions based on guidelines that were 
available during planning of the study (see Data S1). 
NSTEMI was defined according to the third univer-
sal definition for myocardial infarction (MI), including 
a significant rise and fall of cTn with at least 1 value 
above the 99th percentile combined with symptoms 
of ischemia, electrocardiogram changes, and image 
evidence of loss of viable myocardium or intracoro-
nary thrombus.19 Delta values of 20% (baseline cTnT 
concentration >14 ng/L) or 50% (baseline cTnT con-
centration ≤14  ng/L) in serial cTnT measures were 
regarded as significant, as suggested by the ESC in 
2012.17,19 Since 2012, several studies have found a 
significantly lower 99th percentile concentration of 
cTn for women compared with men,20–22 but knowl-
edge of sex-specific cutoffs for women regarding 
diagnosing NSTEMI is partial because of a lack of 
data on pathophysiology.23 Consequently, we chose 
to apply a common cutoff for all patients.
Follow-Up and Prognostic End Points
Follow-up data were collected through the Norwegian 
Patient Register and Norwegian Cause of Death 
Registry. The prognostic end point was a composite 
of all-cause mortality and subsequent nonfatal MI (all 
MIs after the index NSTEMI). Patients were followed 
until an end point occurred or until a median follow-
up time of 723 days after inclusion (ranging from 4 to 
900 days).
Comparator Algorithms
According to current recommendations, patients are 
eligible for early discharge or further investigations 
for ACS based on the troponin results.2 The algo-
rithms encompass an initial review of the admission 
sample in patients who present more than 3 hours 
after symptom onset. If the concentration is below 
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the LOD of the troponin assay, the patient is eligible 
for “rule-out” and may be discharged if the electro-
cardiogram and/or the clinical symptoms suggest a 
lower likelihood of ACS. The remaining patients un-
dergo serial sampling at 1-hour intervals. Based on 
the baseline and delta values obtained, patient status 
is established as “rule-out,” “observation,” or “rule-in” 
for NSTEMI. Again, ruled-out patients may be dis-
charged if the clinical suspicion of ACS is low, those 
who are ruled in may go directly to cardiac angiog-
raphy and eventually invasive treatment, and those 
in the observation group undergo diagnostic follow-
up. We compared the recommended ESC (cTnT and 
cTnI(Abbott)) algorithms
2 and those suggested by Body 
et al14 and Neumann et al15 to the novel algorithms 
described in Tables 1 and 2.
Development of Novel Algorithms
The novel cTnI(sgx) rule-out algorithms were defined 
based on the following hierarchy of criteria: diag-
nostic sensitivity for NSTEMI ≥99.0%, as previously 
described,24 and the maximum possible specificity. 
Sensitivity was preferred over negative predictive value 
as the criterion because sensitivity is independent of 
disease prevalence and applicable in chest pain co-
horts with higher and lower prevalences compared 
with our cohort. Applicable concentrations for the 
rule-in algorithms were based on the following criteria: 
diagnostic specificity for NSTEMI ≥95% (<5% rule-in 
of patients with non-NSTEMI) and a simultaneously 
maximized sensitivity for NSTEMI. Specificity was con-
sidered preferable to positive predictive value because 
specificity is independent of prevalence.
We chose the preferred algorithms based on the 
number of ruled-out and ruled-in patients who would 
give a sensitivity and specificity corresponding to the 
prespecified criteria. “Direct rule-out” was defined 
as rule-out regardless of time since symptom onset. 
Diagnostic performance was calculated with and with-
out early presenters, defined as patients with <3 hours 
since symptom onset.
Statistical Analysis
The baseline characteristics are reported as medians 
with interquartile ranges for continuous data and per-
centages for categorical data. The data were analyzed 
using the nonparametric Kruskal–Wallis test for contin-
uous variables and the chi-square and Fisher’s exact 
test for categorical variables, as appropriate. Statistical 
analyses included calculation of sensitivity, specific-
ity, negative predictive value, positive predictive value, 
and likelihood ratios, receiver operating characteristic 
curve analysis, and calculation of area under the curve 
(AUC) for all algorithms. Significant differences in AUC 
were evaluated using the Delong test, and efficiency Ta
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(defined as percentage of patients ruled out plus per-
centage of patients ruled in) was calculated for all al-
gorithms. Kaplan–Meier curves were drawn for the 
composite end point stratified according to catego-
ries, and the number of events was calculated. Cox 
proportional hazards regression analysis was used to 
calculate the unadjusted hazard ratio for the compos-
ite end point, and adjusted analysis was undertaken 
using age, sex, current or previous smoking, chronic 
kidney disease, hypertension, hyperlipidemia, diabe-
tes mellitus, and previous MI as covariates. Definitions 
of the different risk factors are given in Data S1. We 
used SPSS Statistics 24 and MedCalc for the statisti-
cal analyses.
RESULTS
Baseline Characteristics and Troponin 
Concentrations
The characteristics of patients according to diagnos-
tic category are presented in Table S1 (total cohort, 
n=971) and Table S2 (0/1 hour cohort, n=465). The 
prevalence of NSTEMI was 13%, and the prevalence 
of unstable angina pectoris was 11%. Figure 1 shows 
the median (25 and 75 percentiles) troponin concen-
trations at admission and 1 hour for the three differ-
ent assays. cTnI(sgx) was measurable in 99.9%, cTnT 
in 74%, and cTnI(Abbott) in 87% of samples obtained at 
admission.
Derivation of a Direct Rule-Out and a 
0/1 Hour Rule-Out and Rule-In Algorithm
The number of NSTEMIs that would be ruled out at 
different admission sample cTnI(Sgx) concentrations 
was calculated (see Table S3). A direct rule-out algo-
rithm using <2 ng/L as the cutoff showed a diagnostic 
sensitivity >99%, in accordance with the prespecified 
criteria (Table  1). The 0/1  hour algorithm was devel-
oped in a similar way by calculating the number of 
NSTEMIs ruled out at different admission and delta 
value concentrations combined (see Tables  S4 and 
S5). The optimal rule-out algorithm was a baseline 
cTnI(Sgx) concentration <10  ng/L and a delta value of 
<3 ng/L (Table 2). This algorithm did not rule out any 
patients with NSTEMI and consequently had a sensi-
tivity of 100%, with a corresponding specificity of 89%. 
Of note, this decision threshold is higher than the 99th 
percentile of the assay.
If 8.67 ng/L was used as the baseline concentration 
in the algorithm, the resulting sensitivity was 100% and 
specificity was 87%. Regarding rule-in, the optimal al-
gorithm showed a specificity of 97% using a baseline 
concentration of ≥70 ng/L or a delta value of ≥5 ng/L 
(Table  S5 and Table  2) as cutoffs. An alternative Ta
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algorithm using a lower baseline concentration of 
≥30 ng/L or a delta value of ≥5 ng/L showed similar 
(within 95% CIs) specificity and sensitivity.
Comparing Diagnostic Performance of 
Direct Rule-Out Algorithms
Baseline concentrations analyzed as a continuous 
variable showed a higher AUC for cTnI(Sgx) compared 
with the other assays (Figure 2; Delong test, P≤0.004). 
Direct rule-out by cTnI(Sgx) was the only direct rule-out 
algorithm that fulfilled the criterion of sensitivity >99% 
(Figure 3 and Table 1), and only 1 patient was falsely 
ruled out. A similar sensitivity was achieved for cTnTESC 
when a time lag of 3 hours between testing and symp-
tom onset was applied.
This patient with NSTEMI was inappropriately ruled 
out by all admission algorithms. She was a 65-year-
old woman admitted with chest pain lasting more than 
3 days. A few years earlier, she had been treated with 
percutaneous coronary intervention in all three cor-
onary vessels because of unstable angina pectoris. 
Upon admission, her electrocardiogram showed non-
specific T changes, and she had a high clinical risk for 
ACS (eg, a HEART (History, Electrocardiogram, Age, 
Risk factors, Troponin) score of 7). At 72 hours after 
symptom onset, the baseline troponin samples were 
cTnT 4 ng/L, cTnI(Abbott) 1.5 ng/L, and cTnI(sgx) 1.3 ng/L, 
which increased significantly to cTnT 71 ng/L/, cTnI(Ab-
bott) 80 ng/L, and cTnI(sgx) 56 ng/L after 3 hours. The 
coronary angiogram revealed a thrombus in a small 
vessel that was not available for percutaneous coro-
nary intervention.
The cTnI(Abbott)ESC algorithm had the lowest sensitiv-
ity, missing a second patient, a 73-year-old woman with 
one previous MI. She was admitted to the hospital with 
a history of chest pain related to defecation and base-
line blood samples taken 3.5 hours after symptom onset 
showing cTnT 11  ng/L, cTnI(Abbott) 2  ng/L, and cTnI(sgx) 
9.25 ng/L. After 3 hours, values for cTnI(Abbott) increased 
to 5 ng/L, but cTnT and cTnI(sgx) showed stable values. At 
18 hours after admission, the cTnT increased to 52 ng/L 
and the cTnI to 29 ng/L. Unfortunately, the coronary an-
giography failed because of difficult arterial access.
Comparing Diagnostic Performance 
Between 0/1 Hour Rule-Out and Rule-In 
Algorithms
None of the algorithms ruled out any patient with 
NSTEMI, so that the sensitivity was 100% (Figure 3 and 
Table 2). The novel cTnI(sgx) 0/1 hour rule-out algorithm 
had a higher rule-out rate of patients without NSTEMI 
(higher specificity) and an overall higher AUC (Delong 
test, P<0.001) than comparators.
Concerning the rule-in algorithms, results were 
quite similar for all algorithms: a few patients without 
NSTEMI were ruled in (false positive), for a specificity of 
95% to 97%. However, the cTnTESC 0/1 hour algorithm 
showed a lower AUC (Delong test, P<0.05) compared 
with the cTnI algorithms because of a slightly higher 
number of patients with NSTEMI allocated to the ob-
servation group (lower sensitivity). More than 90% 
of NSTEMIs were ruled in using the cTnI algorithms, 
whereas 78% were ruled in by cTnTESC (Table S6).
Efficiency of the Algorithms
The novel cTnI(sgx) direct rule-out and 0/1  hour algo-
rithms were more efficient than the comparators 
Figure 1. Cardiac troponin concentrations; median, (interquartile range) stratified according to diagnosis.
A, Cardiac troponin concentrations at admission. B, Cardiac troponin concentrations after 1 hour. ACS indicates acute coronary 
syndrome; cTnI(Abbott), cardiac troponin I (Abbott Diagnostics); cTnI(sgx), cardiac troponin I (Singulex Clarity System); cTnT, cardiac 
troponin T; NCCP, non-cardiac chest pain; NSTEMI, non–ST-segment–elevation myocardial infarction; and UAP, unstable angina.
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(Figure  3). The algorithm classified 37% of admitted 
patients as candidates for early discharge, compared 
with 31% with cTnTESC, 23% with cTnI(Abbott)ESC), 24% 
with cTnI(sgx)Body, and 9% with cTnI(sgx)Neumann. When 
the early presenters were excluded for the ESC al-
gorithms in accordance with the guideline, the direct 
rule-out rate dropped to 24% with cTnTESC and 18% 
with cTnI(Abbott)ESC (Figure 3).
Concerning 0/1 hour serial sampling algorithms, the 
novel cTnI(sgx) rule-out algorithm would have suggested 
discharge for 77% of patients, compared with 64% 
with cTnTESC and 57% with cTnI(Abbott)ESC (Table  S4). 
Only 40% would be eligible for discharge if the cTnI(sgx)
Neumann 0/1 hour algorithm were applied. Rule-in would 
be recommended for 13% to 17% (Table S5). Total ef-
ficiency values showed that the novel cTnI(sgx) 0/1 hour 
algorithms would allocate 92% (95% CI, 89%–94%) of 
the patients to either rule-out or rule-in. Corresponding 
numbers for the cTnTESC, cTnI(Abbott) ESC, and cTnI(Neumann) 
0/1  hour algorithms were 78% (95% CI, 74%–82%), 
74% (95% CI, 70%–78%), and 56% (95% CI, 51%–
60%), respectively.
Long-Term Prognostic Value
A total of 82 events occurred among the 971 patients 
included in the admission sample cohort. Table  S7 
shows the number of end points stratified according to 
the different algorithms. With the exception of cTnI(sgx)
Neumann (which allocated only 9% of patients to rule-out), 
the direct rule-out algorithms showed a significant abil-
ity to predict long-term end points. The discrimination 
power of the rule-out algorithms was confirmed in a 
Cox regression analysis (Table 3), after adjustment for 
well-established risk factors.
The 465 patients included in the 0/1  hour cohort 
experienced 32 events. Patients who were ruled out 
by the novel cTnI(sgx) 0/1 hour algorithm had an event 
rate of 5.3% (Table  S7), which was not significantly 
different from the event rate in the observation and 
Figure 2. AUC-ROC for admission troponin concentrations 
as a continuous variable in patients with NSTEMI vs patients 
with non-NSTEMI.
AUC indicates area under the curve; cTnI(Abbott), cardiac troponin I 
(Abbott Diagnostics); cTnI(sgx), cardiac troponin I (Singulex Clarity 
System); cTnT, cardiac troponin T; NSTEMI, non–ST-segment–
elevation myocardial infarction; and ROC, receiver operating 
characteristic curve.
Figure 3. Main diagnostic performance measures and efficiency of the different algorithms.
Diagnostic performance of the admission ESC rule-out algorithm was calculated based on late presenters (n=772) because the 
ESC does not recommend direct rule-out until >3 hours after onset of symptoms. The cardiac troponin I from the Singulex Clarity 
System (cTnI(sgx)) data are based on all participants (N=971). Efficiency was calculated as the percentage eligible for rule-out from the 
total cohort (all algorithms). cTnI(Abbott) indicates cardiac troponin I (Abbott Diagnostics); cTnI(sgx), cardiac troponin I (Singulex Clarity 
System); cTnT, cardiac troponin T; ESC, European Society of Cardiology; and NPV, negative predictive value.
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rule-in groups of 10% to 13% (Figure 4 and Table 3). 
In contrast, those allocated to rule-out by the ESC or 
the Neumann 0/1  hour algorithms had significantly 
lower event rates (1.6%–3.4%) compared with the cor-
responding observation and rule-in groups. Cox re-
gression analysis results confirmed the discrimination 
power of rule-out by these algorithms (Table 3).
DISCUSSION
This study yielded three main findings. First a cardiac 
injury marker with improved analytical sensitivity and 
precision beyond the current high-sensitivity assays 
could improve logistics and categorizing of patients 
investigated for NSTEMI. Second, the cost of this 
screening could be higher rates of rule-out of patients 
with increased long-term risk because of subclinical 
myocardial injury or CMI. Third, our data are in agree-
ment with the proposed ESC algorithms but only partly 
correspond to 2 earlier reports for the cTnI(sgx) assay. 
This pattern highlights a need for robust validation be-
fore rule-in and rule-out algorithms are implemented 
for any particular assay.
Our data suggest that the improved analytical 
sensitivity of the cTnI(sxg) assay translates into a bet-
ter “signal-to-noise ratio” compared with the other 
high sensitivity assays and reduces the time window 
required for reliably detecting myocardial injury. Body 
et al14 reported similar outcomes using a slightly lower 
cutoff than ours (1.5  ng/L). The very low direct rule-
out cutoff suggested by Neumann et al15 was 100% 
sensitive but proved clinically unsuitable in our cohort 
because of the low number of patients eligible for rule-
out (9%). Using a cTnI(sgx) cutoff of <2 ng/L would lead 
to allocation of more patients to direct rule-out than the 
comparator algorithms suggested by ESC and Body et 
al.4,14,25,26
We used a 0/1 rule-out algorithm that depended 
more on delta values and allowed for rule-out at high 
baseline concentrations (>99th percentile of the assay), 
without compromising sensitivity. This approach re-
sulted in a highly specific algorithm, ruling out large 
numbers of patients without NSTEMI. It is noteworthy 
that the novel cTnI(sgx) 0/1 hour algorithm could allocate 
more than 90% of patients to either rule-out or rule-in, 
with a similar or higher diagnostic accuracy compared 
with the other algorithms.
The second important finding in our study is that 
the ability to predict long-term MI and all-cause mor-
tality seems to depend on the algorithm used for 
rule-out. The direct rule-out algorithms that used low 
troponin concentrations as cutoffs showed an ex-
cellent prognostic ability. This finding was robust for 
the cTnI(sgx) and cTnTESC algorithms after adjusting for 
well-known risk factors and borderline significant for 
cTnI(Abbott)ESC.
11,27,28 That the direct rule-out according 
to Neumann et al did not predict long-term prognosis 
may be explained by the low rule-out frequency of 9%.
Concerning the 0/1 hour algorithms, our data sug-
gest that the cTnI(sgx) algorithm could not predict long-
term risk. This algorithm had twice as many end points 
compared with the others. The higher baseline concen-
tration used for rule-out included more patients with 
subclinical myocardial injury (high-normal troponin con-
centrations) and even CMI,5 which could explain this 
observation because these patients have increased 
long-term risk.11,27,28 For all algorithms, we observed a 
similar event rate in patients allocated to observation 
and to rule-in. The prevalence of NSTEMI and CMI was 
Table 3. Cox Regression Analysis
Univariable Multivariable*
HR (95% CI) P Value HR (95% CI) P Value
Direct rule-out (n=971)
cTnTESC <5 ng/L vs observation and rule-in 9.361 (3.423–25.583) <0.001 3.421 (1.170–10.000) 0.025
cTnI(Abbott) ESC <2 ng/L vs observation and rule-in 8.179 (2.582–25.909) <0.001 3.050 (0.917–10.146) 0.069
cTnI(sgx)Neumann <1 ng/L vs observation and rule in 8.296 (1.155–59.609) 0.035 2.365 (0.318–17.583) 0.400
cTnI(sgx) <2 ng/L vs observation and rule-in 7.769 (3.363–17.840) <0.001 3.286 (1.359–7.946) 0.008
0/1 h rule-out (n=465)
cTnTESC <12 ng/L and ∆0–1 <3 ng/L vs observation and rule-in 4.959 (2.294–10.718) <0.001 3.190 (1.345–7.562) 0.008
cTnI(Abbott) ESC <5 ng/L and ∆0–1 <2 ng vs observation and rule-in 3.456 (1.599–7.469) 0.002 2.227 (0.972–5.105) 0.058
cTnI(sgx)Neumann <2 ng/L and ∆0–1 <1 ng/L, vs observation and rule in 6.537 (1.991–21.461) 0.002 3.671 (1.046–12.885) 0.042
cTnI(sgx) <10 ng/L and ∆0–1 <3 ng/L, vs observation and rule-in 2.373 (1.172–4.805) 0.016 1.603 (0.754–3.406) 0.220
95% CI in brackets. Unadjusted and adjusted hazard ratios for the composite end point of future non-fatal myocardial infarction and all-cause mortality. 
Patients are dichotomized based on the admission sample algorithm, that is, rule-out (reference category) vs observation/rule-in. cTnI(Abbott) indicates cardiac 
troponin I (Abbott Diagnostics); cTnI(sgx), cardiac troponin I (Singulex Clarity System); cTnT, cardiac troponin T; ESC, European Society of Cardiology; and HR, 
hazard ratio.
*Included in the multivariable model: algorithm as applicable, age, sex, current or previous smoking, estimated glomerular filtration rate above vs below 
60 mL/min per 1.73 m2, diabetes mellitus, hypertension, hyperlipidemia, and previous MI.
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reciprocal in the two groups, with high NSTEMI fre-
quency in the rule-in group and high CMI frequency in 
the observation group (Tables S6 and S7).27,29 These 
findings highlight that NSTEMI and CMI are both se-
rious conditions with increased long-term risk. Future 
studies should target identifying more accurate diag-
nostic and treatment options for patients with CMI.
The last important observation is the discrep-
ancy between our findings and the data reported by 
Neumann et al.15 The reason could be related to co-
incidence, as the cutoffs in both studies were based 
on the few patients with NSTEMI with low baseline 
concentration. Also, both studies were single center, 
and differences in health care systems could have 
affected the patient cohort that was recruited. The 
fact that Neumann et al also ruled out fewer patients 
for the cTnI(ESC) algorithm suggests that the cohorts 
likely were different. Furthermore, analytical issues 
such as reagent and calibrator lot variations are 
highly likely to influence the performance of cutoffs 
in the low range of an assay.30 This assumption is 
strengthened by the observation that the diagnos-
tic performance for the different rule-in algorithms 
showed better alignment, given that lot-to-lot differ-
ences are usually less prominent at higher cTn con-
centrations. Our data demonstrate the need for large 
sample sets, validation in several different patient 
cohorts, and knowledge about long-term analytical 
performance before rule-in and rule-out algorithms 
are implemented into practice.
An obvious strength of our study is the comparison 
of the cTnI(sgx) algorithm to well-validated algorithms 
Figure 4. Kaplan–Meier curves for the prognostic composite end point of future myocardial infarction (MI) and all-cause 
mortality stratified according to the algorithms.
A, 0/1 hour cTnTESC. B, 0/1 hour cTnI(Abbott)ESC. C, 0/1 hour cTnT(sgx)Neumann. D, 0/1 hour cTnI(sgx). cTnI(Abbott) indicates cardiac troponin I 
(Abbott Diagnostics); cTnI(sgx), cardiac troponin I (Singulex Clarity System); cTnT, cardiac troponin T; and ESC, European Society of 
Cardiology.
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from ESC, including cTnT and another cTnI assay. 
Other strengths are a long observation time during 
the index hospitalization, during which the patients 
were observed for at least 8 hours, ensuring the va-
lidity of the adjudicated diagnosis. The study closely 
mirrored clinical practice by not excluding patients 
with end-stage renal disease or with more than a 12-
hour history of symptoms suggestive of ACS. The last 
strength is a long follow-up period registering end 
points after the index NSTEMI/hospitalization, allowing 
for prognostication.
Study Limitations
The main limitation of the study is that the cTnI(sgx) 
assay currently is no longer available on the market 
because of bankruptcy. The baseline concentrations 
used in the rule-out and rule-in algorithms were cho-
sen based on sensitivity, specificity, and efficiency 
for diagnosing NSTEMI, and more studies are nec-
essary to confirm those concentrations that can in-
dicate subclinical myocardial injury and increased 
long-term risk. The suggested algorithms should 
therefore be taken as an example of possibilities and 
limitations that might be expected from high-preci-
sion cardiac injury markers with measurable con-
centrations in almost all healthy participants. Other 
limitations are the relatively low number of patients 
used for development of the 0/1 hour algorithm, the 
single-center inclusion, the lack of a validation co-
hort, and the relatively low number of early present-
ers. As we have noted, our data should be seen as 
hypothesis-generating and as offering examples, 
and all new high-sensitivity biomarkers and algo-
rithms need extensive validation in multiple cohorts 
before they can be ready for clinical use. Another 
limitation is that cTnT was used as part of the adju-
dication process. This use could have introduced a 
positive bias for the cTnT algorithms and underesti-
mation of the performance of cTnI algorithms. Finally, 
this study involved a long inclusion period, which is 
a common problem in similar studies; however, the 
broad inclusion criteria should ensure a broad and 
representative inclusion. In addition, the NSTEMI rate 
and patient characteristics in this cohort are similar 
to those from comparable studies.31,32
CONCLUSIONS
In this study, we show that cardiac injury markers 
with improved analytical performance may improve 
emergency department efficiency by ruling out and 
ultimately categorizing more patients compared with 
current recommendations and algorithms. Our data 
indicate that patients with increased baseline troponin 
concentrations who might suffer from subclinical 
myocardial injury should not be deemed low risk even 
if they are ruled out for NSTEMI. Future studies should 
aim at simultaneous development of dedicated algo-
rithms identifying both patients with NSTEMI and those 
with increased long-term risk. Our final observation is 
that the intercohort variability in algorithm performance 
should not be underestimated, and validation includ-
ing several different cohorts and clinical settings is 
necessary for all suggested emergency department 
algorithms.
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 Table S1. Baseline characteristics for the total cohort. 
Baseline 
characteristics 
Total 
N=971 
NSTEMI 
127 (13.1) 
UAP 
111 (11.4) 
Other 
diseases 
153 (15.7) 
NCCP 
580 (59.7)  
p-value 
Age, years 63 (52.0-74.0) 70 (57.0-
79.0) 
69 (62.0-
77.0) 
70 (58.0-80.0) 59.0 (49.0-
70.0)  
<0.001 
Male 588 (60.6) 87 (68.5) 83 (74.8) 91 (59.5) 327 (56.4) <0.001 
Hours from 
symptom onset to 
first troponin  
sample  
8.0 (3.4-46.2) 5.2 (2.8-
25.4) 
14.6 (5.5-
81.6) 
8.5 (3.5-47.7) 8.0 (3.3-
45.7) 
<0.001 
Early presenters < 
3 hours 
N=199 (20.5) 
 
N=34 (27) 
 
N=17(15.3) 
 
29 (18.9) 
 
119 (20.5) 
 
0.163 
Percentage of 
patients observed > 
8 hours 
N=941 (96.8) 
 
N=127 (100) 
 
N=110(99.1) 
 
141(92.2) 
 
563 (97.1) 
 
<0.001 
Risk factors*       
Hypertension 403 (41.5) 62 (48.8) 60 (54.1) 64 (41.8) 217 (37.4) 0.003 
Diabetes mellitus 120 (12.4) 22 (17.3) 28 (25.2) 16 (10.5) 54 (9.3) <0.001 
Current smoker 202 (20.8) 23 (18.1) 20 (18.0) 33 (21.6) 124 (21.4) 0.89 
Previous smoking 410 (42.2) 69 (54.3) 59 (53.2) 59 (38.6) 219 (37.8) 0.001 
History       
Previous MI 203 (20.9) 33 (26) 43 (38.7) 28 (24.3) 96 (16.6) <0.001 
Previous PCI 204 (21.0) 29 (22.8) 52 (46.8) 26 (17.0) 97 (16.7) <0.001 
Previous CABG 81 (8.3) 17 (13.4) 28 (25.2) 11 (7.2) 25 (4.3) <0.001 
Previous heart 
failure 
46 (4.7) 8 (6.3) 6 (5.4) 14 (9.2) 18 (3.1) 0.013 
Medication       
Statins/other 
lipidlowering  
385 (39.6) 48 (37.8) 71 (64.0) 61 (39.9) 205 (35.3) <0.001 
 
Diuretics 176 (18.1) 23 (18.1) 30 (27.0) 38 (24.8) 85 (14.7) 0.002 
ACE 
inhibitor/ARB 
 
326 (33.6) 
 
46 (36.2) 
 
50 (45.0) 
 
56 (36.6) 
 
174 (30.0) 
 
0.012 
Beta-blocker 336 (34.6) 45 (35.4) 59 (53.2) 68 (44.4) 164 (28.3) <0.001 
Aspirin 340 (35.0) 54 (42.5) 70 (63.1) 106 (47) 169 (29.1) <0.001 
Oral Anticoagulant 118 (12.2) 12 (9.4) 13 (11.7) 39 (25.5) 54 (9.3) <0.001 
Antithrombotic 
agents 
71 (7.3) 7 (5.5) 22 (19.8) 9 (5.9) 33 (5.7) <0.001 
Baseline 
measurements 
      
BMI, kg/m2  
(n=454) 
26.4 (24.2-
29.7) 
25.9 (24.1-
28.6) 
25.8 (24.5-
29.6) 
27.2 (25.7-
29.3)  
26.3 (24.1-
29.8) 
0.337 
HEART score 4.0 (3.0-5.0) 6.0 (5.0-7.0) 5.0 (4.0-6.0) 4.0 (2.5-6.0) 3.0 (2.0-5.0) <0.001 
Baseline 
biomarkers 
      
Glucose, mmol/L 5.8 (5.3-6.7) 6.5 (5.8-8.0) 5.9 (5.4-6.7) 6.1 (5.5-7.3) 5.6 (5.2-6.4) <0.001 
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eGFR, 
ml/min/1.73m2 
85.2 (70.2-
97.1) 
79.6 (62.8-
92.3) 
77.7 (64.8-
91.4) 
74.3 (58.0-
91.6) 
88.4 (75.9-
100.1) 
<0.001 
cTnT, ng/L 7.0 (3.0-18.0) 47 (23.0-
168.0) 
9 (5.0-18.0) 13 (5.5-24.0) 5 (3.0-9.0) <0.001 
cTnI, ng/L 4.0 (2.1-11.2) 117.7 (26.1-
570.9) 
4.7 (3.1-
10.0) 
8.0  (3.2-18.0) 2.7 (1.7-5.2) <0.001 
cTnI(sgx), ng/L 2.8 (1.5-7.7) 91.0 (23.1-
487.7) 
3.4 (1.9-7.3) 4.8 (2.1-12.2) 2.0 (1.3-3.6) <0.001 
ECG findings       
ST depression 33 (3.4) 17 (13.4) 3(2.7) 7 (4.6) 6 (1.0) <0.001 
ST elevation 15 (1.5) 2( 1.6) 0 7 (4.6) 6 (1.0) <0.001 
T-wave inversion 30 (3.1) 10 (7.9) 6 (5.4) 4 (2.6) 10 (1.7) <0.001 
 
Values are n (%) or median (interquartile range). 
ACE=angiotensin-converting enzyme; ARB=angiotensin receptor blocker; BMI=body mass 
index; cTnI=cardiac troponin I (Abbott Diagnostics); cTnI(sgx)=cardiac troponin I (Singulex 
Clarity system); cTnT=cardiac troponin T; CABG=coronary artery bypass graft; 
eGFR=estimated glomerular filtration rate; HEART score=acronym for History, 
ECG=electrocardiogram, A=age, R=risk factors, T=troponin; NCCP=non-cardiac chest pain; 
NSTEMI=non–ST-elevation myocardial infarction; MI=myocardial infarction; 
PCI=percutaneous coronary intervention; UAP=unstable angina pectoris. 
*Hypercholesterolemia is defined as treatment with lipid-lowering drugs. 
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 Table S2. Baseline characteristics for the 0/1 hour cohort (n=465). 
 
Total 
N=465 
NSTEMI 
61 (13.1) 
UAP 
56 (12.0) 
Other 
diseases 
66 (14.2) 
NCCP 
282 (60.6) 
p-value 
Age, years 61 (51.0-
71.0) 
67 (56.5.0-
78.0) 
68 (62.0-
72.8) 
70 (58.8-
80.0) 
57.0 (49.0-
67.00) 
<0.001 
Male 278 (59.8) 43 (70.5) 47 (83.9) 33 (50.0) 278 (59.8) <0.001 
Hours from 
symptom onset 
to first troponin  
sample  
8.8 (3.5-
49.1) 
5.2 (2.8-
27.6) 
25.4 (7.2-
173.4) 
5.8 (3.3-
26.5) 
8.8 (3.7-
47.9) 
<0.001 
Risk factors*       
Hypertension  199 
(43.1.5) 
28 (45.9) 28 (50.0) 33 (51.6) 110 (39.1) 0.173 
Diabetes mellitus 51 (11.0) 7 (11.5) 16 (28.6) 9 (13.6) 19 (6.7) <0.001 
Current smoker 110 (23.7) 8 (13.1) 13 (23.2) 15 (22.7) 74 (26.3) 0.61 
Previous smoking 189 (40.7) 34 (55.7) 28 (50.0) 31 (47.0) 96 (34.2) 0.018 
Previous PCI 83 (17.8) 12 (19.7) 25 (44.6) 8 (12.1) 38(13.5) <0.001 
Previous CABG 32 (6.9) 9 (14.8) 10 (17.9) 5 (7.6) 8 (2.8) <0.001 
Previous heart 
failure 
14 (3.0) 2 (3.3) 3 (5.4) 4 (6.1) 5 (1.8) 0.170 
Medication       
Statins/other 
lipidlowering  
171 (36.8) 25 (41.0) 33 (58.9) 29 (43.9) 84 (29.8) <0.001 
 
Diuretics 81 (17.4) 9 (14.8) 15 (26.8) 15 (22.7) 42 (14.9) 0.100 
ACE 
inhibitor/ARB 
 
165 (35.5) 
 
19 (31.1) 
 
24 (42.9) 
 
29 (43.9) 
 
93 (33.0) 
 
0.198 
Beta-blocker 147 (31.6) 21 (34.4) 25 (44.6) 33 (50.0) 68 (24.1) <0.001 
Aspirin 154 (33.1) 28 (45.9) 37 (66.1) 22 (33.3) 67 (23.8) <0.001 
Oral 
Anticoagulant 
41 (8.8) 4 (6.6) 3 (5.4) 13 (19.7) 21 (7.4) <0.022 
Antithrombotic 
agents 
31 (6.7) 3 (5.0) 9 (16.1) 4 (6.2) 15 (5.4) <0.057 
Baseline 
measurements 
      
BMI, kg/m2   
(n=231) 
26.4 (24.2-
29.7) 
25.9 (24.1-
28.6) 
25.8 (24.5-
29.6) 
26.3 (24.1-
29.8) 
27.2 (25.7-
29.3) 
0.337 
HEART score 4.0 (2.0-
5.0) 
6.0 (5.0-7.0) 5.0 (4.0-6.0) 4.0 (3.0-5.0) 3.0 (2.0-
4.0) 
<0.001 
Glucose, 
mmol/L 
 
5.8 (5.3-
6.6) 
6.3 (5.7-7.6) 6.1 (5.4-7.6) 6.2 (5.7.5) 5.6 (5.2-
6.2) 
<0.001 
eGFR, 
ml/min/1.73m2 
87.9 (72.4-
98.6) 
86.3 (71.6-
97.0) 
83.1 (69.9-
94.8) 
74.7 (58.0-
93.9) 
90.5 (76.1-
101.2) 
<0.001 
cTnT, ng/L 7.0 (3.0-
16.0) 
49.0 (21.5-
185.0) 
8.5 (5.0-
19.5) 
12 (7.0-20.5) 5 (3.0-8.0) <0.001 
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cTnI(Abbott), ng/L 3.8 (2.0-
10.1) 
144.5 (27.1-
549.2) 
3.9 (2.7-9.9) 8.1 (3.3-
14.9) 
2.7 (1.7-
4.6) 
<0.001 
cTnI(sgx), ng/L 2.6 (1.4-
6.8) 
105.9 (28.4-
501.7) 
2.6(1.8-7.0) 4.6 (2.0-
10.8) 
1.8 (1.2-
3.1) 
<0.001 
ECG findings       
ST depression 10 (2.2) 6 (9.8) 1 (1.8) 1 (1.5) 2  (0.7) <0.001 
ST elevation 3  (0.6) 2 (3.3) 0 (0.0) 1 (1.5) 0 (0.0) <0.001 
T-wave 
inversion 
13 (2.8) 5 (8.2) 4 (7.1) 0 4 (1.4) <0.001 
Values are n (%) or median (interquartile range). 
ACE=angiotensin-converting enzyme; ARB=angiotensin receptor blockers; BMI=body mass 
index; cTnI=cardiac troponin I (Abbott Diagnostics); cTnI(sgx)=cardiac troponin I (Singulex 
Clarity system); cTnT=cardiac troponin T; CABG=coronary artery bypass graft; 
eGFR=estimated glomerular filtration rate; HEART score=acronym for History, 
ECG=electrocardiogram, A=age, R=risk factors, T=troponin; NCCP=non-cardiac chest pain; 
NSTEMI=non–ST-elevation myocardial infarction; MI=myocardial infarction; 
PCI=percutaneous coronary intervention; UAP=unstable angina pectoris. 
*Hypercholesterolemia is defined as treatment with lipid-lowering drugs. 
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 Table S3. Number of patients ruled out using different protocols. 
 NSTEMI  UAP 
 
Non-ACS cardiac 
disease 
Non-cardiac 
chest pain  
Other 
diseases  
Total 
Rule-out, total cohort N=127  N=111  N=73 N=580 N=80  N=971 
cTnTESC < 5 ng/L 2 (2) 20 (18) 6 (8) 247 (43) 23 (29) 298 (31) 
cTnI(Abbott)ESC < 2 ng/L 3 (2) 11 (10) 3 (4) 192 (33) 13 (16) 222 (23) 
cTnI(sgx)Neumann < 1.0 ng/L 0 5 (4.5) 0 76 (13.1) 6 (7.5) 87 (9.0) 
cTnI(sgx)Body < 1.5 ng/L 1 (1) 15 (14) 2 (3.0) 203 (35) 16 (20) 237 (24) 
cTnI(sgx)  < 2 ng/L  1 (1) 31 (28) 6 (8) 293 (51) 29 (36) 360 (37) 
Rule-out, total cohort (all 
early presenters  were 
automatically ruled-in) 
N=127 N=111  N=73 N=580 N=80 N=971 
cTnTESC < 5 ng/L 1 (1) 16 (14) 3 (4) 194 (33) 21 (26) 235 (24) 
cTnI(Abbott)ESC < 2 ng/L 2 (1.5) 9 (8) 2 (3) 149 (26) 12 (15) 174 (18) 
cTnI(sgx)Neumann < 1.0 ng/L 0 3 (3) 0 54 (12) 5 (6) 62 (6) 
cTnI(sgx)Body < 1.5 ng/L 1 (1) 12 (11) 1 (1) 159 (27) 15 (19) 188 (19) 
cTnI(sgx)  < 2 ng/L  1 (1) 24 (22) 4 (5) 231 (40) 26 (33) 286 (29) 
Rule-out, late presenters 
only ( ≥ 3 hours)  
N=93 N=94  N=55 N=461 N=69 N=772  
cTnTESC < 5 ng/L 1 (1) 16 (17) 3 (6) 194 (42) 21 (30) 235 (30) 
cTnI(Abbott)ESC < 2 ng/L 2 (2) 9 (10) 2 (4) 149 (32) 12 (17) 174 (23) 
cTnI(sgx)Neumann < 1.0 ng/L 0 3 (3.2) 0 54 (12) 5 (7) 62 (8) 
cTnI(sgx)Body < 1.5 ng/L 1 (1) 12 (13) 1 (2) 159 (35) 15 (22) 188 (24) 
cTnI(sgx)  < 2 ng/L  1 (1) 24 (26) 4 (7) 231 (50) 26 (38) 286 (37) 
Percentages in brackets. 
The upper panel shows the number of patients who would be ruled out if all patients 
(independent of time between symptom onset and testing) were included.  
Middle panel shows number of rule-outs in the total cohort when all early presenters were 
directly transformed to serial sampling, and the last panel shows the number of rule-outs in 
late presenters only (used for calculation of diagnostic performance in late presenters; see 
Table 1, main text). 
ACS=acute coronary syndrome; cTnI(Abbott)=cardiac troponin I (Abbott Diagnostics); 
cTnI(sgx)=cardiac troponin I (Singulex Clarity system); cTnT=cardiac troponin T; 
ESC=European Society of Cardiology; NCCP=non-cardiac chest pain; NSTEMI=non–ST-
elevation myocardial infarction; UAP=unstable angina pectoris. 
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Table S4. Number of patients ruled in using 0/1 hour protocols. 
Percentages in brackets. 
ESC protocols for cTnT and cTnI(Abbott) and different protocols for cTnI(sgx). 
ACS=acute coronary syndrome; cTnI(Abbott)=cardiac troponin I (Abbott Diagnostics); 
cTnI(sgx)=cardiac troponin I (Singulex Clarity system); cTnT=cardiac troponin T;  
ESC=European Society of Cardiology; NCCP=non-cardiac chest pain; NSTEMI=non–ST-
elevation myocardial infarction; UAP=unstable angina pectoris. 
 
 
 
 
 
 
 
 NSTEMI  UAP 
 
Non-ACS cardiac 
disease 
Non-cardiac 
chest pain  
Other 
diseases  
Total 
0/1 hour rule-out  N=61  N=56  N=30 N=282  N=36  N=465 
Evaluation of cTnESC and Neumann algorithms:  
cTnTESC < 12 ng/L and 
∆0-1 < 3 ng/L 
0 33 (59) 8 (31) 237 (84) 22 (61) 300 (64) 
cTnI(Abbott)ESC < 5 ng/L 
and ∆0-1 < 2 ng/L 
0 32 (57) 6 (20) 212 (75) 14 (39) 264 (57) 
cTnI(sgx)Neumann < 2.0 and 
∆0-1 < 1 ng/L 
0 20 (36) 2 (7) 152 (54) 12 (33) 186 (40) 
Evaluation of cTnI(sgx) baseline and delta values combined: 
cTnI(sgx) < 4.0 and ∆0-1 < 
3 ng/L 
0 35 (64) 8 (27) 230 (82) 19 (53) 293 (63) 
cTnI(sgx) < 6.0 and ∆0-1 < 
3 ng/L 
0 41 (73) 11 (37) 256 (91) 25 (69) 333 (71) 
cTnI(sgx) < 8.0 and ∆0-1 < 
3 ng/L 
0 44 (79) 14 (47) 264 (94) 28 (78) 350 (75) 
cTnI(sgx) < 8.67 and ∆0-1 
< 3 ng/L 
0 44 (79) 15 (50) 264 (94) 29 (81) 352 (76) 
cTnI(sgx) < 10.0 and ∆0-1 
< 3 ng/L 
0 45 (80) 16 (53) 259 (95) 39 (87) 358 (77) 
cTnI(sgx) < 12.0 and ∆0-1 
< 3 ng/L 
1 (2) 46 (82) 19 (63) 268 (95) 31 (86) 365 (78) 
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Table S5. Number of patients ruled in using 0/1 hour protocols. 
 
 NSTEMI  UAP 
 
Non-ACS 
cardiac disease 
Non-cardiac 
chest pain  
Other 
diseases  
Total 
0/1 hour rule-in N=61  N=56  N=30 N=282  N=36  N=465 
cTnTESC≥ 52 ng/L or ∆0-1 
≥ 5 ng/L 
48 (79) 2 (4) 8 (27) 2 (1) 2 (6) 62 (13) 
cTnI(Abbott)ESC ≥ 52 ng/L 
or ∆0-1 ≥ 6 ng/L 
56 (92) 6 (11) 9 (30) 5 (2) 2 (6) 78 (17) 
cTnI(sgx)Neumann ≥ 25.0 
ng/L or ∆0-1 ≥ 6 ng/L 
55 (90) 5 (9) 7  (23) 5  (2) 2 (5) 74 (16) 
Evaluation of cTnI(sgx) baseline and delta values combined: 
cTnI(sgx) ≥ 8.0 or ∆0-1 ≥ 3 
ng/L 
61 (100) 12 (21) 16 (53) 20 (7) 8 (22) 117 (25) 
cTnI(sgx) ≥10.0 or ∆0-1 ≥ 3 
ng/L 
61 (100) 12 (21) 16 (54) 20 (7) 8 (22) 117 (25) 
cTnI(sgx) ≥ 12.0 or ∆0-1 ≥ 3 
ng/L 
60 (98) 10 (18) 11 (37) 16 (6) 5 (14) 102 (22) 
cTnI(sgx) ≥ 14.0 or ∆0-1 ≥ 3 
ng/L 
58 (95) 10 (18) 10 (33) 13 (5) 4 (11) 95 (20) 
cTnI(sgx) ≥ 18.0 or ∆0-1 ≥ 3 
ng/L 
58 (95) 9 (16) 7 (23) 10 (4) 3 (8) 86 (19) 
cTnI(sgx) ≥ 20.0 or ∆0-1 ≥ 3 
ng/L 
58 (95) 8 (14) 7 (23) 10 (4) 3 (8) 86 (19) 
cTnI(sgx) ≥ 30.0 or ∆0-1 ≥ 3 
ng/L 
58 (95) 6 (11) 7 (23) 8 (3) 2 (6) 81 (17) 
cTnI(sgx) ≥ 40.0 or ∆0-1 ≥ 3 
ng/L 
57 (93) 6 (11) 7 (23) 7 (3) 2 (6) 79 (17) 
cTnI(sgx) ≥ 50.0 or ∆0-1 ≥ 3 
ng/L 
57 (93) 6 (11) 7 (23) 7 (3) 2 (6) 79 (17) 
cTnI(sgx) ≥ 60.0 or ∆0-1 ≥ 3 
ng/L 
57 (93) 6 (11) 7 (23) 7 (3) 2 (6) 79 (17) 
cTnI(sgx) ≥ 70.0 or ∆0-1 ≥ 3 
ng/L 
57 (93) 6 (11) 7 (23) 7 (3) 2 (6) 78 (17) 
cTnI(sgx) ≥ 80.0 or ∆0-1 ≥ 3 
ng/L 
57 (93) 4 (7) 6 (20) 4 (1) 2 (6) 73 (16) 
cTnI(sgx) ≥ 90.0 or ∆0-1 ≥ 3 
ng/L 
57 (93) 4 (7) 6 (20) 4 (1) 2 (6) 73 (16) 
cTnI(sgx) ≥ 100.0 or ∆0-1 ≥ 
3 ng/L 
57 (93) 3 (5) 6 (20) 4 (1) 2 (6) 72 (16) 
cTnI(sgx) ≥ 150.0 or ∆0-1 ≥ 
3 ng/L 
57 (93) 2 (4) 6 (20) 4 (19 2 (6) 71 (15) 
       
cTnI(sgx) ≥ 10.0 or ∆0-1 ≥ 5 
ng/L 
60 (98) 11 (20) 14 (47) 13 (5) 5 (14) 103 (22) 
cTnI(sgx) ≥ 20.0 or ∆0-1 ≥ 5 
ng/L 
57 (93) 6 (11) 7 (23) 5 (2) 3 (8) 78 (17) 
cTnI(sgx) ≥ 30.0 or ∆0-1 ≥ 
5 ng/L 
57 (93) 3 (5) 7 (23) 3 (1) 2 (6) 72 (16) 
cTnI(sgx) ≥ 40.0 or ∆0-1 ≥ 5 
ng/L 
55 (90) 3 (5) 7 (23) 2 (1) 1 (3) 68 (15) 
cTnI(sgx) ≥ 50.0 or ∆0-1 ≥ 5 
ng/L 
55 (90) 3 (5) 7 (23) 2 (1) 1 (3) 68 (15) 
cTnI(sgx) ≥ 60.0 or ∆0-1 ≥ 5 
ng/L 
55 (90) 3 (5) 7 (23) 2 (1) 1 (3) 68 (15) 
cTnI(sgx) ≥ 70.0 or ∆0-1 ≥ 
5 ng/L 
55 (90) 3 (5) 6 (20) 2 (1) 1 (3) 67 (14) 
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cTnI(sgx) ≥ 80.0 or ∆0-1 ≥ 5 
ng/L 
55 (90) 3 (5) 6 (20) 2 (1) 1 (3) 67 (14) 
cTnI(sgx) ≥ 90.0 or ∆0-1 ≥ 5 
ng/L 
55 (90) 3 (5) 6 (20) 2 (1) 1 (3) 67 (14) 
cTnI(sgx) ≥ 100.0 or ∆0-1 ≥ 
5 ng/L 
55 (90) 3 (5) 6 (20) 2 (1) 1 (3) 67 (14) 
cTnI(sgx) ≥ 110.0 or ∆0-1 ≥ 
5 ng/L 
55 (90) 3 (5) 6 (20) 2 (1) 1 (3) 67 (14) 
cTnI(sgx) ≥ 120.0 or ∆0-1 ≥ 
5 ng/L 
55 (90) 3 (5) 6 (20) 2 (1) 1 (3) 67 (14) 
cTnI(sgx) ≥ 130.0 or ∆0-1 ≥ 
5 ng/L 
55 (90) 3 (5) 6 (20) 2 (1) 1 (3) 67 (14) 
cTnI(sgx) ≥ 140.0 or ∆0-1 ≥ 
5 ng/L 
55 (90) 3 (5) 6 (20) 2 (1) 1 (3) 67 (14) 
cTnI(sgx) ≥ 150.0 or ∆0-1 ≥ 
5 ng/L 
55 (90) 3 (5) 6 (20) 2 (1) 1 (3) 67 (14) 
cTnI(sgx) ≥ 250.0 or ∆0-1 ≥ 
5 ng/L 
55 (90) 3 (5) 6 (20) 2 (1) 1 (3) 67 (14) 
 
Percentages in brackets. 
ACS=acute coronary syndrome; cTnI(Abbott)=cardiac troponin I (Abbott Diagnostics); 
cTnI(sgx)=cardiac troponin I (Singulex Clarity system);  cTnT=cardiac troponin T;  
ESC=European Society of Cardiology; NCCP=non-cardiac chest pain; NSTEMI=non–ST-
elevation myocardial infarction; UAP=unstable angina pectoris. 
ESC protocols for TnT and cTnI(Abbott) and different protocols for cTnI(sgx). 
  
D
ow
nloaded from
 http://ahajournals.org by on D
ecem
ber 15, 2020
10 
 
 Table S6. Allocation of NSTEMI patients. 
 
Rule-out / rule-in protocol Rule-out Observation Rule-in 
cTnTESC 0/1 hour 0 13 (21.3) 48 (78.7) 
cTnI(Abbott)ESC 0/1 hour 0 5 (8.2) 56 (91.8) 
cTnI(sgx)Neumann 0/1 hour 0 6 (9.8) 55 (90.2) 
cTnI(sgx) 0/1 hour  0 6 (9.8) 55 (90.2) 
Percentages in brackets. 
The table shows the category to which the different 0/1 hour rule-out and rule-in protocols 
would allocate patients who were finally diagnosed with an index NSTEMI (n=61).  
cTnI(Abbott)=cardiac troponin I (Abbott Diagnostics); cTnI(sgx)=cardiac troponin I (Singulex 
Clarity system); cTnT=cardiac troponin T; ESC=European Society of Cardiology; 
NSTEMI=non–ST-elevation myocardial infarction. 
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Table S7. Prevalence of events stratified according to protocol classification. 
 
 None-fatal MI and all-cause mortality 
Direct rule-out N=82 
Rule out  
     cTnT < 5 ng/L 4 (1.4) 
    cTnI(Abbott) < 2 ng/L 3 (1.4) 
    cTnI(sgx)Neumann < 1 ng/L 1 (1.2) 
    cTnI(sgx) < 2 ng/L 6 (1.7) 
  
Observation/rule in  
      cTnT 78 (11.6) 
      cTnI(Abbott) 79 (10.6) 
      cTnI(sgx)Neumann  81 (9.2) 
      cTnI(sgx)  76 (12.4) 
0/1 hour protocol N=32 
Rule-out  
     cTnT < 12 ng/L and ∆0-1 < 3 ng/L 9 (3.0) 
     cTnI(Abbott) < 5 ng/L and ∆0-1 < 2 ng/ 9 (3.4) 
     cTnI(sgx)Neumann < 2 and ∆0-1 < 1 ng/L 3 (1.6) 
     cTnI(sgx) < 10 and ∆0-1  < 3 ng/L 19 (5.3) 
  
Observation  
    cTnT  13 (12.6) 
    cTnI(Abbott) 13 (10.6) 
    cTnI(sgx)Neumann 19 (9.3) 
    cTnI(sgx)  4 (10.0) 
  
Rule-in  
    cTnT ≥52 ng/L or ∆0-1 ≥ 5 ng/L 10 (16.1) 
    cTnI(Abbott) ≥ 52 ng/L or ∆0-1 ≥ 6 ng/L 10 (12.8) 
    cTnI(sgx) ≥ 25.0 or ∆0-1 ≥ 6 ng/L 10 (13.5) 
    cTnI(sgx) ≥ 70.0 or ∆0-1 ≥ 5 ng/L 9 (13.4) 
Percentages in brackets. 
cTnI(Abbott)=cardiac troponin I (Abbott Diagnostics); cTnI(sgx)=cardiac troponin I (Singulex 
Clarity system); cTnT=cardiac troponin T; MI=myocardial infarction. 
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